Submitted by web@researchtop... on Mon, 12/17/2018 - 11:23
Interview with Harold J Burstein, MD, PhD
Interview with Terry Mamounas, MD, MPH
Track 1:
Case: A 58-year-old woman with ER/PR-positive, HER2-negative invasive ductal carcinoma and a RS of 25 receives adjuvant chemotherapy and an aromatase inhibitor
Track 2:
Role of adjuvant chemotherapy for patients with ER-positive, HER2-negative, node-negative BC and an intermediate RS
Track 3:
TAILORx results: Adjuvant chemotherapy guided by the 21-gene assay RS for patients with ER-positive, HER2-negative, node-negative BC
Track 4:
Viewpoint on the clinical utility of the 21-gene assay RS
Track 5:
Comparison of the 21-gene and 70-gene assays
Track 6:
Use of the 21-gene assay for patients with node-positive disease
Track 7:
Case registry analysis of clinical outcomes of patients with ER-positive, HER2-negative, node-positive BC treated according to their 21-gene assay RS
Track 8:
Overview of radiation therapy techniques
Track 9:
Case: A 56-year-old woman with a 1.2-cm ductal carcinoma in situ (DCIS) and a DCIS ScoreTM of 20
Track 10:
Consensus guidelines on margins for breast-conserving surgery for patients with DCIS
Track 11:
Case: A 38-year-old woman with a BRCA1 germline mutation and a family history of breast and peritoneal cancer undergoes prophylactic bilateral nipple-sparing mastectomy
Track 12:
Optimal timing of sentinel lymph node biopsy for patients receiving neoadjuvant chemotherapy
Track 13:
Management of the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy
Track 14:
Monitoring the axilla in patients with early-stage BC not treated with neoadjuvant chemotherapy
Track 15:
Long-term outcomes with neoadjuvant versus adjuvant chemotherapy in early-stage BC
Track 16:
Role of the 21-gene assay RS in guiding neoadjuvant chemotherapy decision-making
Track 17:
Final analysis of the CALOR trial evaluating the efficacy of chemotherapy for isolated locoregional recurrence of BC
Track 18:
Case: A 67-year-old woman with ER/PR-positive, HER2-positive BC achieves a complete clinical and radiologic response to neoadjuvant TCHP
Track 19:
Perspective on the use of (neo)adjuvant pertuzumab
Track 20:
Overview of ongoing NSABP clinical trials in the neoadjuvant and adjuvant settings
FACULTY
Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Terry Mamounas, MD, MPH
Medical Director, Comprehensive Breast Program
Orlando Health UF Health Cancer Center
Professor of Surgery University of Central Florida
Orlando, Florida
EDITOR
Neil Love, MD
Research To Practice
Miami, Florida